Background and Aims While the United States has been experiencing an opioid epidemic, 29 states and Washington
INTRODUCTION
The opioid epidemic is a global problem faced by many European, North American and Oceania countries. In 2016, opioid addiction accounted for more than 55% of years of life lost due to premature death caused by drug abuse [1] . The opioid epidemic in the United States is particularly alarming. It was declared a 'National Public Health Emergency' in October 2017 [2, 3] . The number of opioid prescriptions quadrupled from 76 million to 207 million during 1991-2013 [4] . There was also a parallel escalation in opioid-related mortality rates, hospitalizations and emergency department visits [5, 6] . It was estimated that opioid abuse and overdose imposed 56 billion dollars of annual costs to US society [7] .
Paralleling the opioid epidemic, there was a rapid expansion of medical cannabis legalization in the United States and other countries globally. Since 1996, 29 states and Washington DC in the United States have legalized cannabis for medical use at state level. Country-wide medical cannabis legalization was adopted in Australia, Colombia, Czech Republic, Canada, Uruguay and several other countries. A large body of work examined the impacts of medical cannabis legalization on cannabis-related public health outcomes in the United States, such as cannabis-related perceptions and attitudes, illicit cannabis use, cannabis dependence and abuse, traffic fatalities and health-care utilization, but there is a lack of consistent evidence supporting the associations [8, 9] . The spillover effects of medical cannabis legalization on other drug use has received much less attention.
There is increasing evidence that cannabis has therapeutic effects on pain. Its effectiveness was suggested by systematic reviews of randomized controlled trials [10] [11] [12] [13] [14] and the US National Academies 2017 report [15] . In the United States, where medical cannabis is legal, pain is one of the most commonly approved conditions for patients to request cannabis [16] . Recent research hypothesized that patients may substitute cannabis for pain medications in these states and opioid prescriptions may be impacted as a result [16] [17] [18] [19] [20] [21] . These studies reported emerging evidence in the United States that medical cannabis legalization was associated with considerable reductions in opioid-related outcomes [16] [17] [18] [19] [20] [21] . In particular, two studies utilized administrative records of Medicare and Medicaid enrollees to examine the impacts on drug prescriptions [16, 18] . In the United States, Medicare is a federal health insurance program primarily covering senior people aged 65 years or older, and Medicaid is a joint federal and state program primarily covering people with low income or disabilities. Using Medicare prescription records from 2010 to 2013, in 2016 Bradford & Bradford found that state-wide implementation of medical cannabis legalization was associated with reductions in prescriptions of most drug classes for which cannabis could serve as substitutes, including pain medications [18] . In 2017, Bradford & Bradford provided similar evidence using Medicaid prescription records from 2007 to 2014 [16] . Despite the comprehensive evaluations in these two studies, they categorized pain medications broadly, including not only opioid and non-opioid analgesics but also drugs used primarily to treat other conditions 1 [16, 18] . The specific associations of medical cannabis legalization with opioid prescriptions are unknown. We investigated state-level aggregate prescription drug records from 1993 to 2014, covering almost all years of state-wide legislative activities in medical cannabis legalization in the United States. We tested the hypothesis that legalizing medical cannabis was associated with reductions in opioids received by Medicaid enrollees, a priority group with an excessive burden of chronic pain and high risks for opioid misuse and overdose [22, 23] . We explored the heterogeneity in policy responses by drug schedules. Potential impacts on Medicaid spending were also estimated.
METHODS

Data
This is a secondary data analysis of state-level opioid prescriptions in the United States. The primary data were obtained from 1993-2014 Medicaid State Drug Utilization Data published by the US Centers for Medicare and Medicaid Services (CMS) [24] . The data included quarterly records of out-patient drugs reimbursed by each state's Medicaid program, excluding drugs dispensed in emergency departments or in-patient settings and those paid with cash [24] . Because states' reporting to CMS is required in the Medicaid Drug Rebate Program, the prescription drug records were almost complete in each state and quarter [24] . The 1993-2014 data included 61 million drug records in total.
Study population
The study was restricted to records for Medicaid enrollees who enrolled in fee-for-service programs during 1993-2014. Records for patients enrolled in managed care Medicaid programs were excluded because states' regular reporting on managed care programs did not start until 2010. In the United States, Medicaid covered services are paid directly by the state under the fee-for-service model, whereas the state pays managed care organizations on a per capita basis and the managed care organizations pay providers for all Medicaid-covered services under the managed care model. The Medicaid managed care penetration rate has risen from less than 50% in the 1990s to more than 70% in the 2010s [25] . We excluded the most recent data after 2014, because fee-for-service enrollees for those years were not published at the time of this study.
Measures
Outcome measures
The three primary outcomes were the number of filled opioid prescriptions (including both new prescriptions and refills), dosage of filled opioid prescriptions [in oral morphine milligram equivalents (MME)] [26] and Medicaid spending on opioid prescriptions (in 2014 US dollars). All outcomes were population-adjusted to values per quarter per 100 Medicaid enrollees [27] . The number of Medicaid enrollees in fee-for-service programs in each state was obtained from yearly Medicaid Managed Care Enrollment Reports [25] . To identify opioid prescriptions, the National Drug Code numbers from Medicaid State Drug Utilization Data were linked with drug information [26] ). Methadone was included because it was prescribed typically for pain management in our data source. Nominal Medicaid spending was inflation-adjusted to 2014 constant US dollars [27] . Schedule II and Schedule III opioids were identified based on the current classifications by the US Drug Enforcement Agency and analyzed respectively [30] . Following previous research [26, 27] [32] . More detailed information about US drug schedules can be found in Supporting information, Technical note S1.
Cannabis policy measures
The primary policy variable of interest was the presence of state-wide medical cannabis legalization. The dichotomous policy indicator took the value of 1 if the state had medical cannabis legalization in effect in that quarter and 0 otherwise. During the study period, 23 states and Washington DC implemented medical cannabis legalization. The models also controlled for two additional cannabis-related dichotomous policy indicators: the presence of cannabis decriminalization, under which cannabis use is no longer a criminal offense, and the presence of recreational cannabis legalization, under which the production, sale and consumption of cannabis for recreational purpose is legal. During the study period, two states (Colorado and Washington) had recreational cannabis legalization in effect. Because permitting medical cannabis dispensaries is the major provision that increases direct access to cannabis [33] , we also considered a dichotomous indicator for the presence of any active medical cannabis dispensary. During the study period, 14 states and Washington DC opened their first medical cannabis dispensaries. The effective dates of these policies were obtained from various sources of legal and policy reviews [34] [35] [36] [37] [38] (Supporting information, Table S1 ).
Other state-level covariates
The models also controlled for state-level policy and socioeconomic covariates, including a dichotomous indicator for the presence of the Prescription Drug Monitoring Program that provides a state-wide electronic database to track controlled substances, a dichotomous indicator for the implementation of Medicaid expansion under the Affordable Care Act that expanded Medicaid coverage to all adults with income up to 138% of the federal poverty level, median household income in 2014 constant dollars, the number of active physicians per 1000 population, the percentage of residents with household income below the federal poverty level and unemployment rate [39] [40] [41] (see details in Supporting information, Technical note S2).
Statistical analyses
The data were aggregated and analyzed at state-quarter level. The final state-quarter observations were approximately 4100 for both Schedule II and Schedule III opioids analysis. The descriptive statistics were provided to compare the 23 states and Washington DC that implemented medical cannabis legalization 2 and the 27 states that had not implemented the legalization 3 during the study period.
Two sets of linear time-series regressions (models 1 and 2) were used to assess the associations of implementing medical cannabis legalization with the three opioid prescription outcomes, which were log-transformed to obtain normal distributions [16] . The coefficient of the dichotomous indicator of medical cannabis legalization can be interpreted as the average percentage change in the outcome associated with legalization implementation. To test the robustness of the results, we replaced the dates of implementing medical cannabis legalization with law-passing dates. We added back data outliers to the regressions. Following Bradford & Bradford [16, 18] , we conducted falsification tests on the four classes of drugs used to treat conditions for which cannabis had no proven beneficial (or harmful) effects. 4 To estimate the potential Medicaid cost savings associated with medical cannabis legalization, we calculated the statistically significant changes in Medicaid spending from regressions, then multiplied the annualized changes with the number of fee-for-service enrollees in states that had implemented medical cannabis legalization by the end of 2014. To project nation-wide cost savings, we extrapolated the estimates to all the 50 states and Washington DC, assuming that they all had implemented legalization by 2014. The cost savings were allocated to the federal government and state governments based on Federal Medical Assistance Percentages in 2014 [42] . Cost savings for enrollees in managed care programs were not included in the estimation.
RESULTS
Descriptive statistics
Unadjusted descriptive outcomes for opioid prescriptions per quarter per 100 Medicaid enrollees are presented in Table 1 and Fig. 1 . In terms of the average rates during the 21-year study period, the rates of Schedule II opioids were higher compared to Schedule III opioids and the rates of opioids in states without cannabis legalization were higher compared to those that did adopt cannabis legalization. For Schedule II opioids, there was a downward trend over time in states that did not adopt cannabis legalization and a slight upward trend for states with legalization. For Schedule III opioids, these trends were reversed; sates without legalization had an upward trend while states with legalization showed a slight downward trend. 
Regression results
Sensitivity analysis results
The significant results reported above remained significant in the regressions replacing implementation dates of legalization with law-passing dates (Supporting information, Table S5 ) and in the regressions adding outliers back (Supporting information, Table S6 ). In the falsification tests (Supporting information, Table S7 ), no associations were found between medical cannabis legalization and the number of prescriptions in any of the four drug classes.
DISCUSSION
The findings of this study added to the still limited literature [16] [17] [18] [19] [20] [21] , supporting the hypothesis that state-wide medical cannabis legalization in the United States was associated with reduced opioids received by Medicaid enrollees. Compared to Bradford & Bradford [16] , this study focused specifically on opioid prescriptions and explored the heterogeneity in policy responses by drug classes. The long timespan (1993-2014) included early legalization period in the late 1990s and the early 2000s. Thus, estimates of this study represented the overall policy associations with opioids in both early and late policy adopters.
Our results suggested that medical cannabis legalization was associated with nearly 30% reductions in Schedule III opioids, within the range of estimates in previous research [16] [17] [18] [19] [20] [21] . Nonetheless, there was no evidence supporting legalization's association with Schedule II opioids, which constituted approximately 95% of all opioid prescriptions in the data. With the absence of individual-level information, we were not able to explore the mechanisms underlying the differential associations. Here, we provided tentative explanations for discussions. In the United States, Schedule III opioids are used typically to treat mild to moderate pain and refillable within 6 months without new prescriptions [43] . In contrast, Schedule II opioids must be refilled with new monthly prescriptions because of their higher potential of dependence and abuse, such that patients prescribed Schedule II opioids are required to receive regular monitoring and evaluations from physicians. In addition, evidence suggested that cannabis provides mild to moderate relief from pain, on par with codeine [15] , making cannabis a better alternative to Schedule III opioids. Although there is emerging evidence suggesting that cannabis is effective in treating severe pain [44] [45] [46] [47] [48] , no studies compared the analgesic efficacy of the cannabinoids with Schedule II opioids. Due to the concern of cannabis' lack of efficacy on severe pain symptoms, patients prescribed Schedule II opioids might be less likely to switch to medical cannabis and physicians might be less likely to recommend medical cannabis to these patients. Consistent with previous research [20, 21] , we found no evidence that permitting medical cannabis dispensaries had association with opioid prescriptions after controlling for medical cannabis legalization. One plausible explanation is the co-occurrence of the two policy variables. Of the 23 states and Washington DC, that legalized medical cannabis during the study period, 14 states and Washington DC had active dispensaries and most of these states opened their first dispensaries within 3 years of legalization. The lack of additional variations in policy adoption and timing may have made it challenging to discern statistically the effects of dispensaries independent of the legalization. An alternative explanation is that patients were responsive to the change in the legal status of medical cannabis use but less so to the increased access to cannabis provided in the dispensaries. This hypothesis is unfortunately not testable in the aggregate analyses of this study.
It is worth noting that despite the significant associations with Schedule III opioid prescriptions, medical cannabis legalization had limited implications about Medicaid spending on opioids. This is largely because Schedule III opioids, mostly codeine, only accounted for less than 5% of Medicaid spending on opioid prescriptions. Even if we extrapolated the estimated savings for fee-for-service enrollees to managed care program enrollees, the total annual savings combined would be only $34 million, a modest portion in the total Medicaid spending of $497 million in 2014 [49] . This number would be even smaller if patients' out-of-pocket costs to pay cannabis were considered negative welfare transfer.
Our data did not find a significant association between Prescription Drug Monitoring Programs and opioid prescriptions. This is likely because mandates, enforcement and awareness in early adopters were generally weak [27] . The non-significant findings were also reported in some previous studies [50] [51] [52] , but not all [53, 54] . The research using most recent data sources, however, consistently suggested the program effectiveness in states that adopted best practices [27, [53] [54] [55] [56] [57] .
The study has limitations. First, the findings suggested associations but not causality. Even after we controlled for a rich set of state-level time varying covariates, state and time fixed effects and state-specific time trends, some important differences between states with different legalization status may not be captured successfully [58] .
Secondly, we relied upon aggregate state-level records. Despite the common application in studies of this kind [5, 8, 17, 23, 27, 52] , aggregate data are subject to ecological fallacy, as pointed out by Hall et al. [58] . Without direct observations on individual physician or patient behaviors, inferences cannot be made regarding whether and how individual behaviors responded to policy Figure 1 Unadjusted pre-and post-legalization trends in number of opioid prescriptions per quarter per 100 Medicaid enrollees for states that did and did not legalize medical cannabis during 1993-2014. For the 23 states and Washington DC that legalized medical cannabis, quarter 0 encompasses the date that legalization occurred with trends from time -10 (10 quarter before implementation) to time +10 (10 quarters after implementation) obtained by calculating the average number of opioid prescriptions at each time-point across states. For the 27 states without medical cannabis legalization, 24 computations of before and after trends were calculated in each state using time 0 as the legalization date for each of the states and Washington DC that did legalize. These were then aggregated across states to obtain final projections Table S2 . NA = not available.
changes. In particular, the hypothesis that patients substituted medical cannabis for opioid prescriptions cannot be tested explicitly. Thirdly, following Bradford & Bradford [16] , we focused on fee-for-service Medicaid enrollees and excluded patients enrolled in managed care programs, which constituted the majority (70% or more) of Medicaid enrollees. It is unknown whether our findings would generalize to managed care enrollees. Note, however, that Medicaid cost savings associated with medical cannabis legalization would be underestimated if our results are applicable to that population.
Lastly, the findings may not be generalizable to opioids dispensed in emergency departments or in-patient settings, to Medicaid enrollees in managed care programs or to the general population in the United States. They may not be generalizable to other countries facing similar challenges from opioid epidemic or cannabis legalization, given the differences in drug schedules, prescribing and drug use behaviors, social norms and legal and policy contexts. In particular, the significant results on US-standard Schedule III opioids, most of which were codeine, may not be replicated in countries where codeine was classified into other drug schedules or not commonly used. Furthermore, cannabis for recreational use may be associated with an increased risk of opioid misuse and opioid use disorder [59] , and the findings of this study may be altered after recreational cannabis was legalized.
CONCLUSION
In this study, we found that state-wide medical cannabis legalization implemented in 1993-2014 in the United States was associated with close to 30% reductions in Schedule III opioids received by Medicaid enrollees. The legalization was not associated with changes in Schedule II opioids, resulting in modest overall savings of Medicaid spending. Future research is warranted to utilize individual-level data to understand the causal mechanisms of the findings and replicate the analysis in other countries.
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